Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo

American Journal of Respiratory and Critical Care Medicine

Volumn 175, Issue 6, 2007, Pages 595-603

  Cartwright, Neil ^a   Murch, Oliver ^b   McMaster, Shaun K ^a   Paul Clark, Mark J ^a   Van Heel, David A ^b   Ryffel, Bernhard ^c   Quesniaux, Valerie F J ^c   Evans, Timothy W ^a   Thiemermann, Christoph ^b   Mitchell, Jane A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Transogenose Institute   (France)

Author keywords

Lipopolysaccharides; Pattern recognition; Peptidoglycan; Receptors

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; HEPTANOYL GAMMA DEXTRO GLUTAMYL 2,6 DIAMINOPIMELOYL DEXTRO ALANINE; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; GRAM NEGATIVE SEPSIS; HEART RATE; IN VIVO STUDY; LUNG INJURY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; URINE VOLUME; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WESTERN BLOTTING;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTITHROMBIN III; AORTA; BLOOD PRESSURE; CYTOKINES; HEART RATE; KIDNEY; LIPOPOLYSACCHARIDES; MICE; MULTIPLE ORGAN FAILURE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEUTROPHILS; NITRIC OXIDE SYNTHASE TYPE II; NOD1 SIGNALING ADAPTOR PROTEIN; OLIGOPEPTIDES; PANCREAS; PEPTIDE HYDROLASES; SHOCK;

EID: 33947318655     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200608-1103OC     Document Type: Article

References (35)

1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
3. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003;31:2332-2338.
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.
5. Vincent JL, Abraham E. The last 100 years of sepsis. Am J Respir Crit Care Med 2005;173:256-263.
6. Mitchell JA, Fitzgerald KA, Coyle A, Silverman N, Cartwright N. TOLLing away in Brazil. Nat Immunol 2006;7:675-679.
7. Thiemermann C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 1990;182:591-595.
8. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the LPS gene product. J Immunol 1999;162:3749-3752.
9. Cartwright N, McMaster S, Sorrentino R, Paul-Clark M, Sriskandan S, Ryffel B, Quesniaux V, Evans T, Mitchell J. Elucidation of Toll-like receptor and adapter protein signalling in vascular dysfunction induced by gram positive S. aureus or gram negative E. coli. Shock 2007;27:40-47.
10. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002;162:1028-1032.
11. Arcaroli J, Silva E, Maloney JP, He Q, Svetkauskaite D, Murphy JR, Abraham E. Variant IRAK-1 haplotype is associated with increased nuclear factor-κB activation and worse outcomes in sepsis. Am J Respir Crit Care Med 2006;173:1335-1341.
12. Ii M, Matsunaga N, Hazeki K, Nakamura K, Takashima K, Seya T, Hazeki O, Kitazaki T, Iizawa Y. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro- 4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits Toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 2006;69:1288-1295.
13. Wang JE, Dahle MK, McDonald M, Foster SJ, Aasen AO, Thiemermann C. Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock 2003;20:402-414.
14. Myhre AE, Aasen AO, Thiemermann C, Wang JE. Peptidoglycan: an endotoxin in its own right? Shock 2006;25:227-235.
15. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci USA 1995;92:10359-10363.
16. Travassos LH, Girardin SE, Philpott DJ, Blanot D, Nahori MA, Werts C, Boneca IG. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep 2004;5:1000-1006.
17. Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, Ogura Y, Kawasaki A, Fukase K, Kusumoto S, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003;4:702-707.
18. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem 2003;278:5509-5512.
19. van Heel DA, Hunt KA, Ghosh S, Herve M, Playford RJ. Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease. Eur J Immunol 2006;36:1629-1635.
20. van Heel DA, Ghosh S, Butler M, Hunt KA, Lundberg AM, Ahmad T, McGovern DP, Onnie C, Negoro K, Goldthorpe S, et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 2005;365:1794-1796.
21. Inohara C, McDonald C, Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005;74:355-383.
22. Masumoto J, Yang K, Varambally S, Hasegawa M, Tomlins SA, Qiu S, Fujimoto Y, Kawasaki A, Foster SJ, Horie Y, et al. Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J Exp Med 2006;203:203-213.
23. van Heel DA, Ghosh S, Butler M, Hunt K, Foxwell BM, Mengin-Lecreulx D, Playford RJ. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol 2005;35:2471-2476.
24. Jourdan KB, Evans TW, Lamb NJ, Goldstraw P, Mitchell JA. Autocrine function of inducible nitric oxide synthase and cyclooxygenase-2 in proliferation of human and rat pulmonary artery smooth-muscle cells: species variation. Am J Respir Cell Mol Biol 1999;21:105-110.
25. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, Hutchinson N, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995;81:641-650.
26. Halpern W, Mulvany MJ, Warshaw DM. Mechanical properties of smooth muscle cells in the walls of arterial resistance vessels. J Physiol 1978;275:85-101.
27. Murch O, Collin M, Sepodes B, Foster SJ, Mota-Filipe H, Thiemermann C. Lysophosphatidylcholine reduces the organ injury and dysfunction in rodent models of gram-negative and gram-positive shock. Br J Pharmacol 2006;148:769-777.
28. Ravanat C, Freund M, Schuhler S, Grunert P, Meyer L, Cazenave JP. Species specific immunoassays to measure blood platelet and coagulation activation in the rat. Thromb Haemost 1996;76:1090-1095.
29. Bishop-Bailey D, Larkin SW, Warner TD, Chen G, Mitchell JA. Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. Br J Pharmacol 1997;121:125-133.
30. Patel NS, Cortes U, Di Poala R, Mazzon E, Mota-Filipe H, Cuzzocrea S, Wang ZQ, Thiemermann C. Mice lacking the 110-kD isoform of poly(ADP-ribose) glycohydrolase are protected against renal ischemia/reperfusion injury. J Am Soc Nephrol 2005;16:712-719.
31. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985;14:157-167.
32. Vavricka SR, Musch MW, Chang JE, Nakagawa Y, Phanvijhitsiri K, Waypa TS, Merlin D, Schneewind O, Chang EB. hPepT1 transports muramyl dipeptide, activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 2004;127:1401-1409.
33. Szabo C, Mitchell JA, Thiemermann C, Vane JR. Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 1993;108:786-792.
34. Wu CC, Szabo C, Chen SJ, Thiemermann C, Vane JR. Activation of soluble guanylyl cyclase by a factor other than nitric oxide or carbon monoxide contributes to the vascular hyporeactivity to vasoconstrictor agents in the aorta of rats treated with endotoxin. Biochem Biophys Res Commun 1994;201:436-442.
35. Uehara A, Yang S, Fujimoto Y, Fukase K, Kusumoto S, Shibata K, Sugawara S, Takada H. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 2005;7:53-61.